News & articles

  • Targeting the JAK2V617F hematopoietic stem cell through integrins-based combination

    Advancing Research: Targeting the JAK2V617F Hematopoietic Stem Cell Through Integrins-Based Combination Early in her career, as a veterinarian, Shinobu Matsuura, DVM, PhD, remembers a debilitating case of aplastic anemia in a young German shepherd. It pulled on her heart strings and solidified her belief that bone marrow is the most important organ in the body. … Read More »Targeting the JAK2V617F hematopoietic stem cell through integrins-based combination

    READ MORE

    2023 ASCO Annual Meeting MPN Highlights

    MPNs More Visible Than Ever at ASCO 2023  Recognized as the premier educational and scientific event for the greater oncology community, MPN presentations and posters were more prominent than ever at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.   MPNRF’s presence at ASCO was all encompassing. Our team was there to… Read More »2023 ASCO Annual Meeting MPN Highlights

    READ MORE

    2023 European Hematology Congress MPN Highlights

    2023 European Hematology Congress MPN Highlights The European Hematology Association (EHA) Congress 2023 in Frankfurt, Germany in June, brought more than 10,000 participants together, with a much higher representation of MPN research and clinical advances than in previous years.   In one major session, presentations by leaders of an MPN specialized working group represented the work… Read More »2023 European Hematology Congress MPN Highlights

    READ MORE

    Benefits of Giving to MPN Research in Your Will

    It’s not something most of us think about, but including in your will a gift to a cause you care about, like MPN Research Foundation, has personal benefits for you long before your assets are distributed as you wish.  Four benefits you can collect on now: Lessening anxiety. Thinking and planning ahead can make it… Read More »Benefits of Giving to MPN Research in Your Will

    READ MORE

    AACR Annual Meeting MPN Highlights

    While the Annual Meeting of the American Association for Cancer Research (AACR), held in April 2023, focused a great deal on understanding, decoding, and advocating for cancer health equity and inclusion, there were also significant scientific take-aways important to the treatment of MPNs.  One presentation by Haris Ali, MD, City of Hope Comprehensive Cancer Center,… Read More »AACR Annual Meeting MPN Highlights

    READ MORE

    Preventing Blood Clots in MPNs

    Advancing Research: Preventing Blood Clots in MPNs Blood clots, heart attacks, and strokes are leading causes of death or disability in patients with MPNs, typically as a result of elevated platelets and/or red blood cells. Dr. Joan Beckman’s lab at the University of Minnesota is currently working to determine whether growth-arrest-specific 6 protein (Gas6) contributes… Read More »Preventing Blood Clots in MPNs

    READ MORE

    Today’s Understanding of MPNs: Review Articles in ASH Journal Blood

    Today’s Understanding of MPNs: Article Reviews in ASH Journal Blood The world’s current understanding of myeloproliferative neoplasms (MPNs) is showcased in a review of MPN articles published in the April 2023 issue of the American Society of Hematology (ASH) journal Blood (Vol 141 Number 16: April 20, 2023).  The articles describe the latest advances in the field… Read More »Today’s Understanding of MPNs: Review Articles in ASH Journal Blood

    READ MORE

    An Important Moment in the Treatment of MPNs

    An Important Time for MPNs “This is a profoundly important moment in the treatment of MPNs,” according to Raajit Rampal, MD, PhD, a hematology/oncology specialist at Memorial Sloan Kettering, and MPNRF’s medical advisor. We now have three FDA-approved JAK inhibitors – ruxolitinib, pacritinib, and fedratinib. We have combinations to offer, including a number of new… Read More »An Important Moment in the Treatment of MPNs

    READ MORE

    Nanobody-Based Targeted Therapy

    MPNRF ADVANCING RESEARCH: Nanobody-Based Targeted Therapy Through a 2022 MPNRF Thrive Initiative award, Najla Arshad, PhD, Yale University School of Medicine, will explore Development of Nanobody-Based Targeted Therapy for Myeloproliferative Neoplasm, with funding for up to two years.  “There is a real need for a therapy that can target and eliminate these diseased cells, to… Read More »Nanobody-Based Targeted Therapy

    READ MORE

    Thrive Initiative Press Release

    MPN Research Foundation Awards Additional $1.8 Million for Blood Cancer Research into Myeloproliferative Neoplasms Dec. 14, 2022 (Chicago) − MPN Research Foundation (MPNRF) announces its 2022 Thrive Initiative recipients for projects that fill research funding gaps, some of which surfaced due to the pandemic. This $1.8 million in awards is in addition to currently funded… Read More »Thrive Initiative Press Release

    READ MORE

    1 2 3 4 5 42
  • Join the MPN Research community

    Be the first to know about the latest news and advancements.
    What are the latest developments in MPN Research?